KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will release earnings results for the first quarter before the opening bell on Thursday, Sept. 11.
Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at 96 cents per share, versus a year-ago loss of 87 cents per share. KalVista Pharmaceuticals projects to report quarterly revenue of $2.09 million, according to data from Benzinga Pro.
On Aug. 11, KalVista Pharmaceuticals announced maintenance of Orphan Designation for Sebetralstat in the European Union.
KalVista Pharmaceuticals shares fell 2.2% to close at $15.61 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- HC Wainright & Co. analyst Andrew Fein reiterated a Buy rating with a price target of $27 on July 11, 2025. This analyst has an accuracy rate of 68%.
- JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating and increased the price target from $19 to $27 on July 8, 2025. This analyst has an accuracy rate of 73%.
- Leerink Partners analyst Joseph Schwartz maintained an Outperform rating and boosted the price target from $18 to $20 on July 7, 2025. This analyst has an accuracy rate of 65%.
- Needham analyst Serge Belanger reiterated a Buy rating with a price target of $28 on April 8, 2025. This analyst has an accuracy rate of 75%.
- Citizens Capital Markets analyst Jonathan Wolleben reiterated a Market Outperform rating with a price target of $19 on March 26, 2025. This analyst has an accuracy rate of 73%.
Considering buying KALV stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
